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Background/Aims: Eradication of Helicobacter pylori infec-
tion with standard triple therapy (TT) has declined primar-
ily because of increased antibiotic resistance. Sequential 
therapy (ST) has been suggested as an alternative to TT for 
the first-line treatment of H. pylori. The purpose of this study 
was to compare the efficacy of ST with TT. Methods: This 
was a multicenter, randomized open-label trial performed at 
nine centers in Korea. Patients with H. pylori infection were 
randomly assigned to receive either 7 day TT or 10 day ST. 
Eradication rates, drug compliance, and adverse events were 
compared among the two regimens. Results: A total of 601 
patients were enrolled between March 2011 and September 
2014. The intention-to-treat eradication rates were 70.8% for 
TT and 82.4% for ST (p=0.001). The corresponding per pro-
tocol eradication rates were 76.9% and 88.8% for TT and ST, 
respectively (p=0.000). There were no statistically significant 
differences between the two regimens with respect to drug 
compliance and adverse events. Conclusions: ST achieved 
better eradication rates than TT as a first-line therapy for H. 
pylori eradication in Korea. (Gut Liver 2016;10:556-561)
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INTRODUCTION
Helicobacter pylori is a known cause of gastritis, peptic ulcer, 
mucosa-associated lymphoid tissue lymphoma (MALToma), 
and gastric cancer.1,2 Eradication of H. pylori is essential for the 
treatment of these diseases and is currently recommended in 
numerous guidelines.3-6 Most international guidelines recom-
mended triple therapy (TT) regimens consisting of a proton 
pump inhibitor (PPI), clarithromycin, and amoxicillin/metroni-
dazole for at least 7 days for eradication of H. pylori.7-10 How-
ever the eradication rates of TT has decreased to unacceptable 
levels of less than 80% in the past decade due to increased H. 
pylori resistance to antibiotics.11,12 Although the seroprevalence 
rate of H. pylori has been reported to be decreasing in Korea, it 
is still very common infecting more than half of the adult popu-
lation.13 
The TT regimen is recommend as first line therapy in the re-
cent Korean guidelines and is the only regimen reimbursed by 
the Korean National Health Insurance Service (NHIS).14 Howev-
er, the eradication rates of TT has been reported to be declining 
in Korea similar to the trend shown in other countries.15,16 
The sequential therapy (ST) consists of a PPI and amoxicillin 
for the first 5 days followed by a PPI plus clarithromycin and 
metronidazole (or tinidazole) for the following 5 days.17 The ST 
regimen has been suggested as an alternative first line regimen 
and several systematic reviews have found the ST to be superior 
to TT for eradication of H. pylori.18-21 However, clarithromycin 
resistance is reported to be as high as 37.3% in Korea.22 A meta-
analysis found that although ST achieved higher eradication 
rates than the TT regimens, its eradication rate was lower in 
Korea compared with previous reports.23 However, most of the 
studies included in this meta-analysis were either single center 
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studies or locoregional studies. Thus, we decided to perform a 
nationwide study comparing the eradication rates of ST with TT 
to find out if ST can replace TT as first line therapy in Korea
MATERIALS AND METHODS
1. Study design and population
This was a multicenter, randomized, open-label, and double-
arm study. Patients with confirmed H. pylori infection were 
enrolled from nine tertiary hospitals from March 2011 to Sep-
tember 2014 (Fig. 1). Currently, the NHIS reimburses eradica-
tion therapy for patients diagnosed with peptic ulcer disease or 
gastric MALToma. Consecutive patients (19 to 75 years of age) 
who had received endoscopy at each hospital and who met the 
criteria for eradication by NHIS were candidates for inclusion in 
the study. Patients who had received endoscopic treatment for 
early gastric cancer were also included in our study. Exclusion 
criteria included use of PPI, H2-receptor antagonist, bismuth 
preparation and antibiotics 2 weeks before enrollment, prior 
eradication treatment, history of gastrectomy, and presence of 
severe comorbidities or malignancy. Patients deemed inappro-
priate for inclusion by the investigator were excluded, as were 
patients who refused to participate in the study. All included 
patients provided written informed consent prior to their par-
ticipation. The study was approved by Korean Ministry of Drug 
and Food Safety (11930) along with the ethics committees at 
each participating hospital. This study was registered at Clinical 
Research Information Service (KCT0000378).
2. Detection of H. pylori infection and confirmation of erad-
ication 
All patients underwent upper gastrointestinal endoscopy be-
fore enrollment in this study. H. pylori infection was defined as 
positive if the results of one of the following tests were positive: 
histological assessment of H. pylori by modified Giemsa stain 
according to the Sydney system, and rapid urease test using 
samples from the antrum and distal corpus. H. pylori eradication 
was evaluated by the two tests used for diagnosis or by 13C-urea 
breath test 4 weeks after completion of treatment. 
3. Randomization and intervention
Patients were randomly assigned to two treatment groups in 
a 1:1 ratio using a computerized random sequence when the 
patient agreed to participate in this study. The TT group received 
a full dose PPI such as lansoprazole 30 mg or pantoprazole 40 
mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 
7 days. The ST group received a full dose PPI and amoxicillin 
1 g twice daily for 5 days, followed by a full dose PPI, clar-
ithromycin 500 mg, and metronidazole 500 mg twice daily for 
5 days. Compliance and adverse events were assessed by inter-
view after the end of the treatment. 
4. Measurements and outcomes
The primary endpoint of the study was H. pylori eradication 
rate in the ST group compared to the TT groups. Secondary 
endpoints were adverse effects and compliance to treatment in 
the TT and ST groups.
5. Statistical analysis
The eradication rate of ST and conventional TT was assumed 
to be 80% and 70%, respectively.23 The sample size needed to 
detect a difference of 10% in the eradication between the two 
regimens with a power of 80% and a significance level of 0.05 
was calculated. A drop-out rate of 20% was anticipated. The 
final calculated sample size was 290 patients for each group. 
For intention-to-treat (ITT) analysis, all patients who took the 
Fig. 1. Flow diagram of the partici-
pants included in the study.
TT, triple therapy; ST, sequential 
therapy.
10 Lost to follow-up
1 Withdrawled consent
12 Lost to follow-up
4 Took <80% of drug
284 Complete medication
268 Completed follow-up
9 Lost to follow-up
10 Lost to follow-up




601 Patients enrolled in study
295 Assigned to TT 306 Assigned to ST
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prescription for eradication therapy were included. For the per 
protocol (PP) analysis, patients who had taken <80% of their 
medication were excluded as well as patients who did not return 
for follow-up. Chi-square and Student t-tests were used to com-
pare proportions and means for normally distributed data. For 
all tests, a p-value ≤0.05 was considered as statistically signifi-
cant. SPSS version 12.0 (SPSS Inc., Chicago, IL, USA) was used 
for all statistical analyses.
RESULTS
A total of 601 patients were enrolled in our study, with 295 
randomly assigned to the TT group and 306 to the ST group (Fig. 1). 
Nineteen patients were lost to follow-up and one patient with-
drew consent after receiving their eradication medicine. Among 
the remaining 581 patients, 22 were lost to follow-up, 12 took 
<80% of their medication, and one withdrew consent. Therefore 
the final PP population consisted of 546 patients. Demographic 
and clinical characteristics at baseline were similar between the 
two treatment groups (Table 1). 
In the ITT population, eradication rates were 70.8% in the TT 
group and 82.4% in the ST group (p=0.001) (Table 2). In the PP 
population, eradication rates were 76.9% with TT and 88.8% 
with ST (p=0.000). Bitter taste was the most common adverse 
effect (Table 3). The overall adverse effect rates were similar in 
the TT and ST groups (43.0% vs 44.4%, p=0.718). Adherence to 
Table 1. Baseline Characteristics of Patients
Variable Triple therapy (n=295) Sequential therapy (n=306) p-value
Age, yr 54.07±12.6 54.01±11.8 0.955
Male sex 173 (58.6) 188 (61.4) 0.484
Reason for eradication 0.764*
    Gastric ulcer 148 140
    Duodenal ulcer 102 114
    Gastric+duodenal ulcer  13  15
    Endoscopic treatment of EGCa  29  36
    MALToma  1  0
    Others  2  1
Data are presented as mean±SD or number (%).
EGCa, early gastric cancer; MALToma, mucosa-associated lymphoid tissue lymphoma.
*Fisher exact test.
Table 2. Eradication Rates and Compliance of Standard Triple Therapy and in Sequential Therapy 
Triple therapy Sequential therapy p-value
Eradication of first line treatment
    ITT 209/295 (70.8) 252/306 (82.4) 0.001
    PP 206/268 (76.9) 247/278 (88.8) 0.000
Data are presented as number (%)
ITT, intention-to-treat; PP, per protocol.
Table 3. Adverse Event Profiles of Triple Therapy and Sequential Therapy
Triple therapy Sequential therapy p-value
Bitter taste  81 (28.5)  72 (24.2) 0.242
Nausea 14 (4.9)  34 (11.4) 0.004
Diarrhea  34 (12.0) 22 (7.4) 0.062
Headache  2 (0.7)  8 (2.7) 0.065
Epigastric discomfort  8 (2.8) 11 (3.7) 0.548
General weakness  6 (2.1)  7 (2.4) 0.842
Others  9 (3.1) 13 (4.4) 0.446
Any adverse events 122 (43.0) 132 (44.4) 0.718
Adherence 268 (98.5) 278 (97.2) 0.280
Data are presented as number (%).
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the medication was also similar between the TT and ST groups 
(98.5% vs 97.2%, p=0.280).
DISCUSSION
ST demonstrated better eradication rates than TT in both 
ITT and PP analyses in the present nationwide study. Adverse 
events and treatment compliance were not statistically different 
between the two treatments. The efficacy of ST is challenged by 
metronidazole resistance and dual resistance to clarithromycin 
and metronidazole.24 In Korea, resistance to both antibiotics is 
high with resistance rates of 16.0% to 37.0% for clarithromycin 
and 35.8% to 56.3% for metronidazole.22,25,26 Dual resistance to 
clarithromycin and metronidazole is reported to be 3.2%.25 The 
main reason that TT is still recommended as first-line therapy in 
Korea is because although ST achieved higher eradication rates 
than TT it did not reach optimal results in previous studies.23 
The present nationwide multicenter study examined whether ST 
could replace TT as first-line therapy in Korea. 
In the PP population, ST achieved eradication rates of 88.8% 
compared to 76.9% for TT. The absolute risk reduction was 
12.0% (95% confidence interval [CI], 5.7 to 18.2) and the num-
ber needed to treat was 9 (95% CI, 5.5 to 18.2). These results in-
dicate that ST can replace TT as first-line therapy in Korea. An-
other concern of ST is the development of antibiotic resistance 
and the choice of the second-line regimens after failure of ST. 
Several studies from Europe reported levofloxacin containing 
triple regimens to be effective as a second-line treatment.27-30 
However, fluoroquinolone resistance is reported to be as high 
as 22.3% to 34.6% in Korea.22,25 Moxifloxacin containing TT 
following failed first-line ST achieved disappointing eradication 
rates of 60.4% and 70.7% for ITT and PP populations in Korea.31 
Bismuth-based quadruple therapy (BQT) may be an alternative 
to levofloxacin-based regimens after failed ST. However, BQT 
should be used for 14 days after failed ST, since metronidazole 
resistance is suspected in these patients.32 Future studies regard-
ing the optimal second line regimen after failure of ST may be 
needed before ST can be regarded as first line therapy.
TT is no longer effective in many parts of the world due to 
increasing clarithromycin resistance and has been deemed as an 
unethical comparator in clinical trials.12,33 However, a 7-day TT 
regimen is the only regimen reimbursed by the NHIS and is the 
most prescribed eradication regimen in Korea. A recent Korean 
study reported final PP eradication rates of TT to be 98.4% after 
second-line treatment and 99% after third-line treatment.34 Al-
though TT regimens may not achieve adequate eradication rates 
as first-line therapies, H. pylori infection was eradicated in most 
patients following second-line and third-line treatment. Non-
BQT such as ST and concomitant therapy may achieve higher 
eradication rates compared to TT as first-line therapy. However, 
it is doubtful that the ultimate eradication rates of these regi-
mens will surpass that of TT. Currently most studies regarding 
first line therapy focus on the efficacy of a regimen as initial 
treatment. However, we believe that the cumulative eradication 
rates of a treatment are equally important. The use of non-BQT 
would expose patients to increased antibiotics which may result 
in increased antibiotic resistance after treatment. For these rea-
sons, TT may be considered as a first-line regimen for H. pylori 
infection in Korea. 
The main limitation of our study was the lack of evalua-
tion of antibiotic resistance in the patients. However, antibiotic 
resistance testing is rarely performed before prescribing first-
line regimens. So, the study mimics routine clinical practice. 
As mentioned above, 7-day TT is the most prescribe regimen in 
Korea and the only regimen reimbursed by the NHIS. Therefore, 
we chose this regimen as the comparator to ST; thus the dura-
tion of TT was shorter than ST. A recent meta-analysis reported 
that ST was superior to 7-day TT but was not significantly bet-
ter than 14-day TT.35 Results of our study may have been dif-
ferent if the duration of TT was increased. Finally, the PPIs that 
were used in our study varied and this may have affected the 
eradication rates. We were not able to unify the PPIs because 
different institutions participated in our study. However, the ef-
ficacy of different PPIs for eradication have been reported to be 
similar in Korea and we believe the different PPIs would have a 
minimal effect on the eradication rates.36 
In conclusion, this nationwide multicenter study suggests that 
ST achieves higher eradication rates than TT as first-line therapy 
in Korea. However, the PP eradication rates of the ST regimen 
was less than 90% and little data exists regarding the optimal 
treatment regimen after failed ST. Further studies are needed to 
determine if it is worthwhile to include an additional antibiotic 
for first line therapy.
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